Bellevue Group AG
Filing Date
Global Rank
#762
/ 8,586
▼ 77
Top Industry
Biotechnology
61.5%
3Y Alpha vs SPY
-12.6%
Period ended 3 months ago
Filed May 15, 2026 · 32d
25 quarters · since Mar 2020
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+28.3%
SPY
+78.1%
Annualised alpha
-12.6%
Max drawdown
−25.1%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
154 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
7.2%
−0.6 pts
Top 5
25.9%
−8.0 pts
Top 10
42.0%
−8.8 pts
HHI
278
Diversified−80
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.7% | $4,190,955,692 |
| Energy | 0.1% | $2,947,754 |
| Technology | 0.1% | $2,547,209 |
| Unclassified | 0.0% | $1,755,918 |
| Financial Services | 0.0% | $1,405,531 |
| Consumer Cyclical | 0.0% | $1,196,721 |
| Consumer Defensive | 0.0% | $563,316 |
| Communication Services | 0.0% | $90,293 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | +3,275,960 | 3,280,000 | $119,129,600 | |
| RARE | Ultragenyx Pharmaceutical Inc. | +2,377,420 | 2,380,000 | $49,861,000 | |
| VRDN | Viridian Therapeutics, Inc.DE | +2,367,617 | 6,726,144 | $131,563,376 | |
| GILD | Gilead Sciences, Inc. | +1,117,127 | 1,169,879 | $163,046,036 | |
| AMGN | Amgen Inc | +276,869 | 295,358 | $103,921,712 | |
| REGN | Regeneron Pharmaceuticals, Inc. | +264,746 | 278,674 | $215,314,678 | |
| MDT | Medtronic plc | +190,737 | 957,329 | $82,952,557 | |
| JBIO | Jade Biosciences, Inc. | +160,399 | 3,501,502 | $49,196,103 | |
| MRK | Merck & Co., Inc. | +114,474 | 206,591 | $24,850,831 | |
| KRYS | Krystal Biotech, Inc. | +71,462 | 481,785 | $124,454,701 | |
| PFE | Pfizer Inc | +50,788 | 107,635 | $3,022,390 | |
| RPRX | Royalty Pharma plc | +25,095 | 38,296 | $1,837,059 | |
| MDLN | Medline Inc. | +18,915 | 136,635 | $6,080,257 | |
| NUVL | Nuvalent, Inc. | +15,800 | 1,053,268 | $107,907,306 | |
| WAY | Waystar Holding Corp. | +14,405 | 256,139 | $6,175,511 | |
| VERA | Vera Therapeutics, Inc. | +12,619 | 1,710,771 | $68,824,316 | |
| OLMA | Olema Pharmaceuticals, Inc. | +12,541 | 16,443 | $245,165 | |
| DNLI | Denali Therapeutics Inc. | +10,628 | 17,766 | $341,107 | |
| MLYS | Mineralys Therapeutics, Inc. | +9,548 | 29,374 | $795,741 | |
| DHR | Danaher Corp /De/ | +7,531 | 202,164 | $38,330,294 | |
| TXG | 10x Genomics, Inc. | +7,432 | 329,492 | $6,995,115 | |
| TVTX | Travere Therapeutics, Inc. | +5,072 | 8,899 | $264,389 | |
| TMDX | TransMedics Group, Inc. | +3,254 | 101,139 | $10,054,227 | |
| CRSP | CRISPR Therapeutics AG | +3,136 | 5,016 | $238,611 | |
| ALKS | Alkermes plc. | +2,276 | 8,870 | $313,643 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
25 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | −3,461,263 | 1,544,456 | $150,198,346 | |
| IONS | Ionis Pharmaceuticals Inc | −2,983,534 | 1,818,665 | $136,563,554 | |
| CLDX | Celldex Therapeutics, Inc. | −2,417,669 | 1,200,000 | $38,064,000 | |
| NBIX | Neurocrine Biosciences Inc | −1,698,658 | 4,646 | $612,064 | |
| TNGX | Tango Therapeutics, Inc. | −1,527,670 | 2,400,000 | $50,208,000 | |
| WVE | Wave Life Sciences Ltd. | −1,485,257 | 5,261 | $38,142 | |
| RLAY | Relay Therapeutics, Inc. | −550,122 | 7,795,242 | $77,562,657 | |
| SRRK | Scholar Rock Holding Corp | −472,019 | 3,584,573 | $176,217,608 | |
| ADPT | Adaptive Biotechnologies Corp | −221,909 | 76,181 | $1,057,392 | |
| PRVA | Privia Health Group, Inc. | −221,460 | 226,703 | $4,663,280 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | −211,360 | 234,543 | $77,603,241 | |
| EW | Edwards Lifesciences Corp | −203,645 | 839,451 | $67,223,236 | |
| ABT | Abbott Laboratories | −165,280 | 1,151,635 | $118,238,365 | |
| ARGX | Argenx SE | −148,854 | 313,000 | $228,568,250 | |
| BDX | Becton Dickinson & Co | −143,775 | 121,887 | $19,164,293 | |
| SYK | Stryker Corp | −143,340 | 217,237 | $71,381,905 | |
| GPCR | Structure Therapeutics Inc. | −138,364 | 6,803 | $327,904 | |
| PEN | Penumbra Inc | −123,128 | 12,267 | $4,028,114 | |
| GKOS | GLAUKOS Corp | −116,232 | 145,703 | $15,686,384 | |
| BSX | Boston Scientific Corp | −92,712 | 1,466,894 | $92,047,598 | |
| MASI | Masimo Corp | −88,532 | 8,753 | $1,556,896 | |
| ZBH | Zimmer Biomet Holdings, Inc. | −83,109 | 155,571 | $14,066,729 | |
| TEVA | Teva Pharmaceutical Industries Ltd | −77,781 | 250,082 | $7,532,469 | |
| DXCM | Dexcom Inc | −58,639 | 788,766 | $49,534,504 | |
| PHR | Phreesia, Inc. | −52,221 | 130,992 | $1,097,712 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
19 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | 2,320,867 | $90,977,986 | |
| PCVX | Vaxcyte, Inc. | 1,190,697 | $69,191,402 | |
| DMRA | Damora Therapeutics, Inc. | 2,298,000 | $59,518,200 | |
| IRON | Disc Medicine, Inc. | 459,314 | $29,368,537 | |
| ORKA | Oruka Therapeutics, Inc. | 507,008 | $24,868,742 | |
| GLUE | Monte Rosa Therapeutics, Inc. | 1,250,000 | $20,562,500 | |
| LIVN | LivaNova PLC | 186,185 | $11,833,918 | |
| RNA | Atrium Therapeutics, Inc. | 263,096 | $3,517,593 | |
| EQNR | Equinor ASA | 17,573 | $741,580 | |
| XOM | Exxon Mobil Corp | 4,370 | $741,414 | |
| BP | Bp PLC | 15,644 | $735,268 | |
| SHEL | Shell plc | 7,844 | $729,492 | |
| PRAX | Praxis Precision Medicines, Inc. | 1,757 | $566,087 | |
| AGMB | Agomab Therapeutics NV | 50,000 | $524,500 | |
| CNTA | Centessa Pharmaceuticals plc | 9,030 | $358,671 | |
| HALO | Halozyme Therapeutics, Inc. | 3,857 | $249,277 | |
| ABVX | Abivax S.A. | 1,048 | $116,694 | |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | 6,982 | $62,488 | |
| QGEN | Qiagen N.V. | 243 | $9,729 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
25 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| FOLD | AMICUS THERAPEUTICS, INC. | 10,735,195 | $152,869,176 | |
| MAZE | Maze Therapeutics, Inc. | 887,708 | $36,777,742 | |
| CDNA | CareDx, Inc. | 431,070 | $8,121,358 | |
| MOH | Molina Healthcare, Inc. | 46,626 | $8,091,476 | |
| ICLR | Icon PLC | 24,560 | $4,475,323 | |
| BMRN | Biomarin Pharmaceutical Inc | 65,008 | $3,863,424 | |
| BTSG | BrightSpring Health Services, Inc. | 92,095 | $3,448,957 | |
| NEO | Neogenomics Inc | 278,286 | $3,272,643 | |
| AVTR | Avantor, Inc. | 276,266 | $3,166,008 | |
| BEAM | Beam Therapeutics Inc. | 111,510 | $3,091,056 | |
| VKTX | Viking Therapeutics, Inc. | 68,665 | $2,415,634 | |
| ROIV | Roivant Sciences Ltd. | 108,039 | $2,344,446 | |
| BKD | Brookdale Senior Living Inc. | 167,444 | $1,806,720 | |
| SIBN | SI-BONE, Inc. | 90,331 | $1,781,327 | |
| EXAS | EXACT SCIENCES CORP | 16,062 | $1,631,256 | |
| CMPS | COMPASS Pathways plc | 142,243 | $981,476 | |
| ANET | Arista Networks, Inc. | 4,800 | $628,944 | |
| META | Meta Platforms, Inc. | 800 | $528,072 | |
| DOCS | Doximity, Inc. | 11,817 | $523,256 | |
| LULU | lululemon athletica inc. | 2,240 | $465,494 | |
| PLTR | Palantir Technologies Inc. | 2,500 | $444,375 | |
| CORT | Corcept Therapeutics Inc | 10,495 | $365,226 | |
| PLNT | Planet Fitness, Inc. | 3,173 | $344,175 | |
| EXEL | Exelixis, Inc. | 7,361 | $322,632 | |
| GH | Guardant Health, Inc. | 3,004 | $306,828 | |
| No positions match the current search. | ||||
1 positions ·
$563,316 total
· Consumer Defensive only
· as of Mar 31, 2026
All sectors
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Technology
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PG |
PROCTER & GAMBLE Co
Consumer Defensive
|
Held | 3,900 | $563,316 | 100.00% |